{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:24:03Z","timestamp":1791239043774,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Microbiology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.tim.2010.02.004","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T05:10:30Z","timestamp":1268111430000},"page":"195-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":261,"title":["Therapy for fungal diseases: opportunities and priorities"],"prefix":"10.1016","volume":"18","author":[{"given":"David W.","family":"Denning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tim.2010.02.004_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"Aids"},{"key":"10.1016\/j.tim.2010.02.004_bib2","first-page":"936","article-title":"Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis","volume":"13","author":"Agarwal","year":"2009","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1469-0691.2003.00489.x","article-title":"Microbial natural products as a source of antifungals","volume":"9","author":"Vicente","year":"2003","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.tim.2010.02.004_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(01)08728-1","article-title":"Penicillin as a chemotherapeutic agent","volume":"236","author":"Chain","year":"1940","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2010.02.004_bib5","unstructured":"Medoff, G. and Kobayashi, G.A. (1980) The Polyenes in Antifungal Chemotherapy. John Wiley & Sons"},{"key":"10.1016\/j.tim.2010.02.004_bib6","first-page":"579","article-title":"Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies","volume":"3","author":"Donovick","year":"1955","journal-title":"Antibiot. Annu."},{"key":"10.1016\/j.tim.2010.02.004_bib7","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/jps.21179","article-title":"Amphotericin B formulations and drug targeting","volume":"97","author":"Torrado","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tim.2010.02.004_bib8","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1128\/AAC.47.12.3917-3925.2003","article-title":"Comparative drug disposition, urinary pharmacokinetics and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits","volume":"47","author":"Groll","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jac\/dkp140","article-title":"Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation","volume":"64","author":"Gershkovich","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib10","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00241-06","article-title":"Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations","volume":"50","author":"Groll","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2010.02.004_bib14","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1128\/AAC.00491-08","article-title":"In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus","volume":"52","author":"Verweij","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7326\/0003-4819-77-1-43","article-title":"5-fluorocytosine in the treatment of mycotic infections","volume":"77","author":"Vandevelde","year":"1972","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib16","doi-asserted-by":"crossref","unstructured":"Hope, W.W. (2010) Flucytosine (5-fluorocytosine; 5FC). In Kucers\u2019 the Use of Antibiotics","DOI":"10.1201\/b13787-184"},{"key":"10.1016\/j.tim.2010.02.004_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/AAC.2.3.114","article-title":"In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata","volume":"2","author":"Normark","year":"1972","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","article-title":"Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis","volume":"83","author":"Stamm","year":"1987","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib19","doi-asserted-by":"crossref","unstructured":"Perfect, J.R. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 291\u2013322","DOI":"10.1086\/649858"},{"key":"10.1016\/j.tim.2010.02.004_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/CMR.1.2.187","article-title":"Overview of medically important antifungal azole derivatives","volume":"1","author":"Fromtling","year":"1988","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.tim.2010.02.004_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1365-2125.1996.03085.x","article-title":"Pharmacokinetics of fluconazole in people with HIV infection: a population analysis","volume":"41","author":"McLachlan","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tim.2010.02.004_bib22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib23","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/09546630510025932","article-title":"Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole","volume":"16","author":"Dastghaib","year":"2005","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.tim.2010.02.004_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0002-9343(89)90475-0","article-title":"Treatment of invasive aspergillosis with itraconazole","volume":"86","author":"Denning","year":"1989","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/j.1875-9114.1998.tb03856.x","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers","volume":"18","author":"Barone","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tim.2010.02.004_bib27","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tim.2010.02.004_bib28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-2008-1063858","article-title":"Update on azole antifungals","volume":"29","author":"Zonios","year":"2008","journal-title":"Semin. Respir. Crit. Care. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1439-0507.2004.00959.x","article-title":"Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis","volume":"47","author":"Eisen","year":"2004","journal-title":"Mycoses"},{"key":"10.1016\/j.tim.2010.02.004_bib30","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug monitoring","volume":"49","author":"Lestner","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: a broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tim.2010.02.004_bib35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib40","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1126\/science.6547247","article-title":"Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase","volume":"224","author":"Petranyi","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.tim.2010.02.004_bib41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/archderm.138.3.353","article-title":"Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study","volume":"138","author":"Sigurgeirsson","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.tim.2010.02.004_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1439-0507.2003.00878.x","article-title":"Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery","volume":"46","author":"Gosbell","year":"2003","journal-title":"Mycoses"},{"key":"10.1016\/j.tim.2010.02.004_bib43","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2010.02.004_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/AAC.46.1.12-23.2002","article-title":"Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia","volume":"46","author":"Petraitiene","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib45","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/378745","article-title":"Attributable mortality of nosocomial candidemia, revisited","volume":"37","author":"Gudlaugsson","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib46","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jinf.2009.08.020","article-title":"Excess mortality, length of stay and cost attributable to candidaemia","volume":"59","author":"Hassan","year":"2009","journal-title":"J. Infect."},{"key":"10.1016\/j.tim.2010.02.004_bib47","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib48","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2010.02.004_bib49","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib50","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.00262-08","article-title":"A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility","volume":"52","author":"Garcia-Effron","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib51","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib52","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1128\/AAC.49.8.3264-3273.2005","article-title":"Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates","volume":"49","author":"Park","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib53","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/AAC.01653-05","article-title":"Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1","volume":"50","author":"Balashov","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1086\/649901","article-title":"Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein","volume":"201","author":"Baquir","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/313583","article-title":"Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group","volume":"30","author":"Kauffman","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/B:MYCO.0000038436.51918.d9","article-title":"Candiduria in hospital patients: a study prospective","volume":"158","author":"Kobayashi","year":"2004","journal-title":"Mycopathologia"},{"key":"10.1016\/j.tim.2010.02.004_bib58","doi-asserted-by":"crossref","first-page":"b2289","DOI":"10.1136\/bmj.b2289","article-title":"Assessing candiduria in a critically ill patient","volume":"338","author":"Hope","year":"2009","journal-title":"Br. Med. J."},{"key":"10.1016\/j.tim.2010.02.004_bib59","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ijid.2008.10.012","article-title":"Bladder irrigation with amphotericin B and fungal urinary tract infection-systematic review with meta-analysis","volume":"13","author":"Tuon","year":"2009","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1086\/313580","article-title":"Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group","volume":"30","author":"Sobel","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib61","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1086\/320531","article-title":"Nosocomial candiduria: a review","volume":"32","author":"Lundstrom","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib62","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1086\/592578","article-title":"Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial","volume":"47","author":"Hamza","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib63","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","article-title":"A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis","volume":"33","author":"Villanueva","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib64","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1086\/423377","article-title":"A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients","volume":"39","author":"de Wet","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib65","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib66","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/bmj.308.6944.1609","article-title":"Vulvovaginal candidiasis in young women with cystic fibrosis","volume":"308","author":"Sawyer","year":"1994","journal-title":"Br. Med. J."},{"key":"10.1016\/j.tim.2010.02.004_bib67","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1067\/S0002-9378(03)00726-9","article-title":"Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine","volume":"189","author":"Sobel","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.tim.2010.02.004_bib68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/sti.77.3.212","article-title":"Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections","volume":"77","author":"White","year":"2001","journal-title":"Sex Transm. Infect."},{"key":"10.1016\/j.tim.2010.02.004_bib69","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1517\/14740338.2.5.475","article-title":"Antifungal drugs in pregnancy: a review","volume":"2","author":"Moudgal","year":"2003","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.tim.2010.02.004_bib70","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib71","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib72","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/clinids\/12.6.1147","article-title":"Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases","volume":"12","author":"Denning","year":"1990","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib73","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib74","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis","volume":"29","author":"Wingard","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib75","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib76","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9343(94)90023-X","article-title":"NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis","volume":"97","author":"Denning","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib78","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib79","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib80","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1371\/journal.ppat.0020035","article-title":"A drug-sensitive genetic network masks fungi from the immune system","volume":"2","author":"Wheeler","year":"2006","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tim.2010.02.004_bib81","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1086\/589304","article-title":"Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure","volume":"198","author":"Hohl","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib82","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/589305","article-title":"Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae","volume":"198","author":"Lamaris","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib83","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s10156-007-0524-9","article-title":"Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with micafungin","volume":"13","author":"Ouchi","year":"2007","journal-title":"J. Infect. Chemother."},{"issue":"Suppl 3","key":"10.1016\/j.tim.2010.02.004_bib84","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1086\/376526","article-title":"Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review","volume":"37","author":"Denning","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib85","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1378\/chest.06-2441","article-title":"Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients","volume":"131","author":"Camuset","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.tim.2010.02.004_bib86","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/322791","article-title":"Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis","volume":"184","author":"Crosdale","year":"2001","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib87","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1744-313X.2006.00616.x","article-title":"Cytokine profiling of pulmonary aspergillosis","volume":"33","author":"Sambatakou","year":"2006","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.tim.2010.02.004_bib88","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1515\/CCLM.2007.033","article-title":"Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis","volume":"45","author":"Vaid","year":"2007","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib89","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jinf.2005.08.022","article-title":"The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis","volume":"52","author":"Jain","year":"2006","journal-title":"J. Infect."},{"key":"10.1016\/j.tim.2010.02.004_bib90","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","article-title":"Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism","volume":"5","author":"Snelders","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.tim.2010.02.004_bib91","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2010.02.004_bib92","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mai.2003.1388","article-title":"Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial","volume":"111","author":"Wark","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.tim.2010.02.004_bib93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1164\/rccm.200805-737OC","article-title":"Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study","volume":"179","author":"Denning","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.tim.2010.02.004_bib94","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1086\/593194","article-title":"Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda","volume":"47","author":"Longley","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib95","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/649861","article-title":"Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi","volume":"50","author":"Nussbaum","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib96","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib97","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib98","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2010.02.004_bib99","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/AAC.00361-09","article-title":"Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis","volume":"53","author":"Spellberg","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2010.02.004_bib100","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1086\/597400","article-title":"Phaeohyphomycosis in a tertiary care cancer center","volume":"48","author":"Ben-Ami","year":"2009","journal-title":"Clin. Infect. Dis."}],"container-title":["Trends in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X10000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X10000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:37:55Z","timestamp":1760812675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966842X10000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0966842X10000211"],"URL":"https:\/\/doi.org\/10.1016\/j.tim.2010.02.004","relation":{},"ISSN":["0966-842X"],"issn-type":[{"value":"0966-842X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy for fungal diseases: opportunities and priorities","name":"articletitle","label":"Article Title"},{"value":"Trends in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tim.2010.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}